2024
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Fathi A, Issa G, Wang E, Erba H, Altman J, Balasubramanian S, Roboz G, Schiller G, McMahon C, Palmisiano N, Juckett M, Madanat Y, Rotta M, Pratz K, Yaghmour G, Nadiminti K, Wei H, Riches M, Corum D, Leoni M, Dale S, Zeidan A. Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood 2024, 144: 2880-2880. DOI: 10.1182/blood-2024-199170.Peer-Reviewed Original ResearchAcute myeloid leukemiaDecreased neutrophil countDecreased platelet countNPM1 mutationsKMT2A-rAdverse eventsCRC ratesClinical activityR/R patientsData cutoffQTc prolongationPlatelet countMyeloid leukemiaNucleophosmin 1Neutrophil countDifferentiation syndromeComposite complete remission rateCycle 1 day 8R/R acute myeloid leukemiaTreatment-emergent adverse eventsDose of venetoclaxInhibitor-naive patientsDose-escalation cohortsDose-expansion phaseComplete remission rate
2023
Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
Daver N, Stein A, Bixby D, Chai-Ho W, Zeidner J, Maher K, Stevens D, Stahl M, Yee K, Curran E, Ito S, Sochacki A, Sallman D, Hernandez R, Metenou S, Ma B, Kato K, Zeidan A. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood 2023, 142: 4278. DOI: 10.1182/blood-2023-173991.Peer-Reviewed Original ResearchR AMLAcute myeloid leukemiaTreatment-emergent AEsInfusion-related reactionsDose-limiting toxicityDose-escalation cohortsHR-MDSDose-dependent increaseComplete remissionObjective responseAnti-tumor activityBone marrowHypomethylating agentAllo-HCTAML ptsEvaluable ptsEscalation cohortsDose escalationRelapsed/Refractory Acute Myeloid LeukemiaMedian age 70 yearsMorphologic leukemia-free statePhase 1 dose escalationSIRPα-Fc fusion proteinRefractory acute myeloid leukemiaMarrow complete remission